Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H24O4 |
| Molecular Weight | 304.3808 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)OC(=O)CCC[C@H](O)C#C\C=C\C=C\[C@H](O)CC#C
InChI
InChIKey=ZVOCIIHCJJEFRQ-BHXBHYJPSA-N
InChI=1S/C18H24O4/c1-4-10-16(19)11-7-5-6-8-12-17(20)13-9-14-18(21)22-15(2)3/h1,5-7,11,15-17,19-20H,9-10,13-14H2,2-3H3/b6-5+,11-7+/t16-,17-/m1/s1
| Molecular Formula | C18H24O4 |
| Molecular Weight | 304.3808 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
Resolvin E1 (RvE1 or RX-10001) is a trihydroxy eicosapentaenoic acid metabolite that has a role as an anti-inflammatory agent and a human xenobiotic metabolite. This compound binds to leukotriene B4 (BLT-1) on neutrophils and to ERV-1/ChemR23 on monocyte/macrophages. Resolvin E1 has been shown to reverse experimental periodontitis and dysbiosis in rats. Furthermore, in a murine model of Alzheimer’s disease, Resolvin E1 (in combination with lipoxin A4) decreased neuroinflammation. Resolvin E1 was also suggested as a potential therapeutic target for psoriasis. A phase I clinical trial to test drug safety in healthy volunteers has been completed in 2009.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Resolvins: natural agonists for resolution of pulmonary inflammation. | 2011-01 |
|
| Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. | 2010-10 |
|
| Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. | 2010-05 |
|
| Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. | 2007-03-15 |
|
| Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. | 2005-03-07 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:45:23 GMT 2025
by
admin
on
Wed Apr 02 08:45:23 GMT 2025
|
| Record UNII |
Q7789B8MWM
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10241
Created by
admin on Wed Apr 02 08:45:23 GMT 2025 , Edited by admin on Wed Apr 02 08:45:23 GMT 2025
|
PRIMARY | |||
|
1251537-11-7
Created by
admin on Wed Apr 02 08:45:23 GMT 2025 , Edited by admin on Wed Apr 02 08:45:23 GMT 2025
|
PRIMARY | |||
|
46926878
Created by
admin on Wed Apr 02 08:45:23 GMT 2025 , Edited by admin on Wed Apr 02 08:45:23 GMT 2025
|
PRIMARY | |||
|
C174874
Created by
admin on Wed Apr 02 08:45:23 GMT 2025 , Edited by admin on Wed Apr 02 08:45:23 GMT 2025
|
PRIMARY | |||
|
Q7789B8MWM
Created by
admin on Wed Apr 02 08:45:23 GMT 2025 , Edited by admin on Wed Apr 02 08:45:23 GMT 2025
|
PRIMARY | |||
|
300000037013
Created by
admin on Wed Apr 02 08:45:23 GMT 2025 , Edited by admin on Wed Apr 02 08:45:23 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> DERIVATIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|